A Phase 3 interventional study of Anifrolumab and Placebo in Active Systemic Lupus Erythematosus, sponsored by AstraZeneca. Completed at 113 sites in 15 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-01-10.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing anifrolumab in Lupus Erythematosus, Systemic — 9 open to participants now, 11 under way, 6 of them phase 3. anifrolumab · Lupus Erythematosus, Systemic.
Among the 20 studies testing anifrolumab in Lupus Erythematosus, Systemic, this one is the 5th largest by enrollment, is one of 2 that started in 2015, is one of 9 in phase 3, and was the 4th registered.
1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
Browse Lupus Erythematosus, Systemic studies →9 of the 20 studies testing anifrolumab in Lupus Erythematosus, Systemic are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Australia, Belgium, Chile and 7 more countries
Ages 5–17
AstraZeneca · Sites in United States, Argentina, Australia and 32 more countries
Ages 5–80
AstraZeneca · Sites in China
Ages 18–70
AstraZeneca · Sites in United States, Canada, France and 6 more countries
Ages 18–70
AstraZeneca · Sites in United States
Ages 18–130 · Women only
By country, each count listing its studies:
anifrolumab: first FDA approval 2021 (SAPHNELO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 2 started in 2015.
This study's enrollment of 373 is above the median of 52 across 878 interventional studies indexed under Lupus Erythematosus, Systemic.
Median enrollment 159 across the 20 interventional studies. Of the 8 that completed or were terminated, 7 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 20 have an industry lead sponsor. The 5 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
46 studies in Lupus Erythematosus, Systemic by AstraZeneca: 19 open now, 25 under way, 6 of them phase 3. Of 20 finished, 11 (55%) have results posted.
Among the 46 studies in Lupus Erythematosus, Systemic by AstraZeneca, this one is the 6th largest by enrollment of the 26 interventional ones that give a count, is one of 2 that started in 2015, is one of 9 in phase 3, and was the 9th registered.
AstraZeneca’s Lupus Erythematosus, Systemic studies by the year they started, since 2008.
4 of the studies testing anifrolumab in Lupus Erythematosus, Systemic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05138133Phase 3AstraZenecaPhase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis | 2027-02-23 |
| NCT05440422National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD | 2027-08-01 |
| NCT06594068AstraZenecaProspective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users | 2027-08-31 |
| NCT07913919University of CambridgeEffect of Anifrolumab on Arterial Inflammation in Systemic Lupus Erythematosus Study | 2027-09-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 20 studies testing anifrolumab in Lupus Erythematosus, Systemic, from their registry updates:
Among AstraZeneca’s 46 in Lupus Erythematosus, Systemic:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment regimen of anifrolumab versus placebo in adult participants with moderately to severely active, autoantibody-positive systemic lupus erythematosus (SLE).
This is a Phase 3, multicentre, multinational, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of an intravenous treatment regimen of anifrolumab versus placebo in participants with moderately to severely active, autoantibody-positive systemic lupus erythematosus (SLE) while receiving standard of care (SOC) treatment. Participants must be taking either 1 or any combination of the following: oral corticosteroids (OCS), antimalarial, and/or immunosuppressants. The study will be performed in adult participants aged 18 to 70 years of age.
Approximately 360 participants receiving SOC treatment will be randomised in a 1:1 ratio to receive a fixed intravenous dose of anifrolumab 300 mg or placebo every 4 weeks for a total of 13 doses (Week 0 to Week 48), with the primary endpoint evaluated at the Week 52 visit. Investigational product will be administered as an intravenous infusion (IV) via an infusion pump over a minimum of 30 minutes, every 4 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Currently receiving at least 1 of the following:
(i) Azathioprine ≤200 mg/day (ii) Antimalarial (eg, chloroquine, hydroxychloroquine, quinacrine) (iii) Mycophenolate mofetil ≤2 g/day or mycophenolic acid ≤1.44 g/day (iv) Oral, subcutaneous (SC), or intramuscular methotrexate ≤25 mg/week (v) Mizoribine ≤150 mg/day
Fulfils at least 4 of the 11 ACR modified 1982 classification criteria for SLE, at least 1 of which must be:
At Screening, Disease Activity Adjudication Group confirmation of:
SLEDAI-2K Criteria: SLEDAI-2K score ≥6 points and "Clinical" SLEDAI-2K score ≥4 points. The "Clinical" SLEDAI-2K is the SLEDAI-2K assessment score without the inclusion of points attributable to any urine or laboratory results including immunologic measures.
Exclusion Criteria:
Receipt of any of the following:
(a) Intra-articular, intramuscular or IV glucocorticosteroids within 6 weeks prior to Day 1
History of cancer, apart from:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anifrolumab 300 mg intravenous infusion (IV) administered every 4 weeks for a total of 13 doses.
Biological: Anifrolumab
Placebo intravenous infusion (IV) administered every 4 weeks for a total of 13 doses.
Drug: Placebo
Intravenous infusion (IV)
Intravenous infusion (IV)
Number of Participants Who Achieved the British Isles Lupus Assessment Group Based Composite Lupus Assessment (BICLA) Response at Week 52
Composite endpoint BICLA was defined by meeting all of the following criteria: * Reduction of all baseline British Isles Lupus Assessment Group (BILAG)-2004 A to B/C/D and baseline BILAG-2004 B to C/D, and no BILAG-2004 worsening in other organ systems, as defined by ≥1 new BILAG-2004 A or ≥2 new BILAG-2004 B * No worsening from baseline in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), where worsening is defined as an increase from baseline of \>0 points in SLEDAI-2K * No worsening from baseline in participants' lupus disease activity, where worsening is defined by an increase ≥0.30 points on a 3-point Physician's Global Assessment (PGA) visual analogue scale (VAS) * No discontinuation of investigational product * No use of restricted medications beyond the protocol allowed threshold before assessment
Time frame: Baseline; Week 52
Number of Participants Who Achieved the British Isles Lupus Assessment Group Based Composite Lupus Assessment (BICLA) Response at Week 52 in the IFN Test-High Sub-group
Defined by meeting all of the following criteria: * Reduction of all baseline British Isles Lupus Assessment Group (BILAG)-2004 A to B/C/D and baseline BILAG-2004 B to C/D, and no BILAG-2004 worsening in other organ systems, as defined by ≥1 new BILAG-2004 A or ≥2 new BILAG-2004 B * No worsening from baseline in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), where worsening is defined as an increase from baseline to \>0 points in SLEDAI-2K * No worsening from baseline in participants' lupus disease activity, where worsening is defined by an increase ≥0.30 points on a 3-point Physician's Global Assessment (PGA) visual analogue scale (VAS) * No discontinuation of investigational product * No use of restricted medications beyond the protocol allowed threshold before assessment
Time frame: Baseline; Week 52
Number of Participants Who Achieved and Maintained an Oral Corticosteroids (OCS) Dose of ≤7.5 mg/Day at Week 52 in the Sub-Group of Participants With Baseline OCS ≥10 mg/Day
Maintained OCS reduction was defined by meeting all of the following criteria: * Achieve an OCS dose of ≤7.5 mg/day prednisone or equivalent by Week 40 * Maintain an OCS dose ≤7.5 mg/day prednisone or equivalent from Week 40 to Week 52 * No discontinuation of investigational product * No use of restricted medications beyond the protocol allowed threshold before assessment
Time frame: Week 40; Week 52
Number of Participants With a ≥50% Reduction in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Activity Score at Week 12 in The Sub-Group of Participants With Baseline CLASI Activity Score of ≥10
50% reduction in CLASI activity score compared to baseline was defined by meeting all of the following criteria: * Achieve ≥50% reduction of CLASI activity score at Week 12 compared to baseline * No discontinuation of investigational product * No use of restricted medications beyond the protocol allowed threshold before assessment
Time frame: Baseline; Week 12
Number of Participants With ≥50% Reduction in Joint Counts at Week 52 in The Sub-group of Participants With ≥6 Swollen and ≥6 Tender Joints at Baseline
50% reduction in the number of swollen and tender joints compared to baseline was defined by meeting all of the following criteria: * Achieve ≥50% reduction from baseline in the number of swollen and tender joints, separately * No discontinuation of investigational product * No use of restricted medications beyond the protocol allowed threshold before assessment
Time frame: Baseline; Week 52
Annualised Flare Rate Through 52 Weeks
A flare was defined as either 1 or more new British Isle Lupus Assessment Group (BILAG-2004) A or 2 or more new BILAG-2004 B items compared to the previous visit. The occurrence of a new flare was checked for each available visit versus the previous available visit up to Week 52. If no new flares occurred, the number of flares was set to 0. Otherwise all flares were counted leading to the maximum number of flares of 13. The annualized flare rate was calculated as the number of flares divided by the flare exposure time in days multiplied with 365.25 (1 year). The flare exposure time is the time up to Week 52 (date of BILAG-2004 assessment at Week 52) or up to the date of last available BILAG-2004 assessment.
Time frame: Baseline to Week 52
Number of Participants With One or More Adverse Events (AEs)
An AE is the development of an undesirable medical condition or the deterioration of a pre-existing medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the product. AEs were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose \[Week 48\]), or until Week 52 for participants who enrolled onto the long term extension (LTE). The reported value is inclusive of serious and non-serious AEs.
Time frame: Baseline to end of study (Maximum of 60 weeks)
Number of Participants With One or More Adverse Events of Special Interest (AESIs)
An AESI is an adverse event (AE) of scientific and medical concern specific to understanding biologics. An AESI may be serious or non-serious. AESI are serious infections, including non-opportunistic serious infections, opportunistic infections, anaphylaxis, malignancy, herpes zoster, tuberculosis (TB) (including latent TB), influenza, vasculitis (non-systemic lupus erythematosus \[SLE\]), and major adverse cardiovascular events (MACE) (including stroke, myocardial infarction \[MI\], or cardiovascular death). AESIs were collected throughout the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose \[Week 48\]), or until Week 52 for participants who enrolled onto the long term extension (LTE).
Time frame: Baseline to end of study (Maximum of 60 weeks)
Number of Participants With a Potentially Clinically Important Change From Baseline in Vital Sign Measurements
Vital sign measurements included oral temperature, blood pressure (BP), pulse rate, and respiratory rate. Vital signs were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose \[Week 48\]), or until Week 52 for participants who enrolled onto the long term extension (LTE).
Time frame: Baseline to end of study (Maximum of 60 weeks)
Number of Participants With a Potentially Clinically Important Change From Baseline in Clinical Laboratory Tests
Clinical laboratory tests were analyzed in a central clinical laboratory and included hematology, serum chemistry and urinalysis tests. Laboratory values were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose \[Week 48\]), or until Week 52 for participants who enrolled onto the long term extension (LTE).
Time frame: Baseline to end of study (Maximum of 60 weeks)
Participants took part in the trial at 119 sites in 15 countries worldwide.
| Milestone | Anifrolumab 300 mg | Placebo |
|---|---|---|
| Started | 181 | 184 |
| Received study drug | 180 | 182 |
| Completed | 156 | 136 |
| Not completed | 25 | 48 |
| Withdrew: Adverse event | 4 | 7 |
| Withdrew: Condition under investigation worsened | 1 | 4 |
| Withdrew: Study specific withdrawal criteria | 1 | 0 |
| Withdrew: Lack of efficacy | 2 | 8 |
| Withdrew: Lost to follow-up | 1 | 3 |
| Withdrew: Severe non-compliance to protocol | 0 | 1 |
| Withdrew: Withdrawal by subject | 11 | 19 |
| Withdrew: Miscellaneous | 5 | 4 |
| Withdrew: Failure to meet randomization criteria | 0 | 2 |
Composite endpoint BICLA was defined by meeting all of the following criteria: * Reduction of all baseline British Isles Lupus Assessment Group (BILAG)-2004 A to B/C/D and baseline BILAG-2004 B to C/D, and no BILAG-2004 worsening in other organ systems, as defined by ≥1 new BILAG-2004 A or ≥2 new BILAG-2004 B * No worsening from baseline in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), where worsening is defined as an increase from baseline of \>0 points in SLEDAI-2K * No worsening from baseline in participants' lupus disease activity, where worsening is defined by an increase ≥0.30 points on a 3-point Physician's Global Assessment (PGA) visual analogue scale (VAS) * No discontinuation of investigational product * No use of restricted medications beyond the protocol allowed threshold before assessment
| Participants | Anifrolumab 300 mg | Placebo |
|---|---|---|
| Number of Participants Who Achieved the British Isles Lupus Assessment Group Based Composite Lupus Assessment (BICLA) Response at Week 52 | 86 | 57 |
Defined by meeting all of the following criteria: * Reduction of all baseline British Isles Lupus Assessment Group (BILAG)-2004 A to B/C/D and baseline BILAG-2004 B to C/D, and no BILAG-2004 worsening in other organ systems, as defined by ≥1 new BILAG-2004 A or ≥2 new BILAG-2004 B * No worsening from baseline in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), where worsening is defined as an increase from baseline to \>0 points in SLEDAI-2K * No worsening from baseline in participants' lupus disease activity, where worsening is defined by an increase ≥0.30 points on a 3-point Physician's Global Assessment (PGA) visual analogue scale (VAS) * No discontinuation of investigational product * No use of restricted medications beyond the protocol allowed threshold before assessment
| Participants | Anifrolumab 300 mg | Placebo |
|---|---|---|
| Number of Participants Who Achieved the British Isles Lupus Assessment Group Based Composite Lupus Assessment (BICLA) Response at Week 52 in the IFN Test-High Sub-group | 72 | 46 |
Maintained OCS reduction was defined by meeting all of the following criteria: * Achieve an OCS dose of ≤7.5 mg/day prednisone or equivalent by Week 40 * Maintain an OCS dose ≤7.5 mg/day prednisone or equivalent from Week 40 to Week 52 * No discontinuation of investigational product * No use of restricted medications beyond the protocol allowed threshold before assessment
| Participants | Anifrolumab 300 mg | Placebo |
|---|---|---|
| Number of Participants Who Achieved and Maintained an Oral Corticosteroids (OCS) Dose of ≤7.5 mg/Day at Week 52 in the Sub-Group of Participants With Baseline OCS ≥10 mg/Day | 45 | 25 |
50% reduction in CLASI activity score compared to baseline was defined by meeting all of the following criteria: * Achieve ≥50% reduction of CLASI activity score at Week 12 compared to baseline * No discontinuation of investigational product * No use of restricted medications beyond the protocol allowed threshold before assessment
| Participants | Anifrolumab 300 mg | Placebo |
|---|---|---|
| Number of Participants With a ≥50% Reduction in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Activity Score at Week 12 in The Sub-Group of Participants With Baseline CLASI Activity Score of ≥10 | 24 | 10 |
50% reduction in the number of swollen and tender joints compared to baseline was defined by meeting all of the following criteria: * Achieve ≥50% reduction from baseline in the number of swollen and tender joints, separately * No discontinuation of investigational product * No use of restricted medications beyond the protocol allowed threshold before assessment
| Participants | Anifrolumab 300 mg | Placebo |
|---|---|---|
| Number of Participants With ≥50% Reduction in Joint Counts at Week 52 in The Sub-group of Participants With ≥6 Swollen and ≥6 Tender Joints at Baseline | 30 | 34 |
A flare was defined as either 1 or more new British Isle Lupus Assessment Group (BILAG-2004) A or 2 or more new BILAG-2004 B items compared to the previous visit. The occurrence of a new flare was checked for each available visit versus the previous available visit up to Week 52. If no new flares occurred, the number of flares was set to 0. Otherwise all flares were counted leading to the maximum number of flares of 13. The annualized flare rate was calculated as the number of flares divided by the flare exposure time in days multiplied with 365.25 (1 year). The flare exposure time is the time up to Week 52 (date of BILAG-2004 assessment at Week 52) or up to the date of last available BILAG-2004 assessment.
| Annualized flare rate ratio | Anifrolumab 300 mg | Placebo |
|---|---|---|
| Annualised Flare Rate Through 52 Weeks | 0.43 (0.31 to 0.59) | 0.64 (0.47 to 0.86) |
An AE is the development of an undesirable medical condition or the deterioration of a pre-existing medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the product. AEs were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose \[Week 48\]), or until Week 52 for participants who enrolled onto the long term extension (LTE). The reported value is inclusive of serious and non-serious AEs.
| Participants | Anifrolumab 300 mg | Placebo |
|---|---|---|
| Number of Participants With One or More Adverse Events (AEs) | 162 | 154 |
An AESI is an adverse event (AE) of scientific and medical concern specific to understanding biologics. An AESI may be serious or non-serious. AESI are serious infections, including non-opportunistic serious infections, opportunistic infections, anaphylaxis, malignancy, herpes zoster, tuberculosis (TB) (including latent TB), influenza, vasculitis (non-systemic lupus erythematosus \[SLE\]), and major adverse cardiovascular events (MACE) (including stroke, myocardial infarction \[MI\], or cardiovascular death). AESIs were collected throughout the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose \[Week 48\]), or until Week 52 for participants who enrolled onto the long term extension (LTE).
| Participants | Anifrolumab 300 mg | Placebo |
|---|---|---|
| Number of Participants With One or More Adverse Events of Special Interest (AESIs) | 29 | 20 |
Vital sign measurements included oral temperature, blood pressure (BP), pulse rate, and respiratory rate. Vital signs were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose \[Week 48\]), or until Week 52 for participants who enrolled onto the long term extension (LTE).
| Participants | Anifrolumab 300 mg | Placebo |
|---|---|---|
| Number of Participants With a Potentially Clinically Important Change From Baseline in Vital Sign Measurements | 45 | 45 |
Clinical laboratory tests were analyzed in a central clinical laboratory and included hematology, serum chemistry and urinalysis tests. Laboratory values were collected throughout the duration of the study, from baseline until end of follow-up (a maximum of 12 weeks post last dose \[Week 48\]), or until Week 52 for participants who enrolled onto the long term extension (LTE).
| Participants | Anifrolumab 300 mg | Placebo |
|---|---|---|
| Number of Participants With a Potentially Clinically Important Change From Baseline in Clinical Laboratory Tests | 72 | 87 |
Collected over Day 1 to end of study (Maximum of 60 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Anifrolumab 300 mg | 1/180 (0.6%) | 16/180 (8.9%) | 125/180 (69.4%) |
| Placebo | 0/182 (0%) | 34/182 (18.7%) | 99/182 (54.4%) |
| Event | Anifrolumab 300 mg | Placebo |
|---|---|---|
| PneumoniaInfections and infestations | 3/180 | 7/182 |
| Systemic lupus erythematosusMusculoskeletal and connective tissue disorders | 1/180 | 6/182 |
| Gastroenteritis viralInfections and infestations | 2/180 | 0/182 |
| Radius fractureInjury, poisoning and procedural complications | 0/180 | 2/182 |
| Acute coronary syndromeCardiac disorders | 1/180 | 0/182 |
| Chilaiditi's syndromeGastrointestinal disorders | 1/180 | 0/182 |
| HypersensitivityImmune system disorders | 1/180 | 0/182 |
| AppendicitisInfections and infestations | 1/180 | 0/182 |
| DiverticulitisInfections and infestations | 1/180 | 0/182 |
| Herpes zosterInfections and infestations | 1/180 | 0/182 |
| Event | Anifrolumab 300 mg | Placebo |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 42/180 | 19/182 |
| NasopharyngitisInfections and infestations | 28/180 | 23/182 |
| Urinary tract infectionInfections and infestations | 21/180 | 26/182 |
| Infusion related reactionInjury, poisoning and procedural complications | 25/180 | 14/182 |
| BronchitisInfections and infestations | 23/180 | 8/182 |
| HeadacheNervous system disorders | 11/180 | 18/182 |
| SinusitisInfections and infestations | 13/180 | 9/182 |
| Herpes zosterInfections and infestations | 12/180 | 3/182 |
| Back painMusculoskeletal and connective tissue disorders | 11/180 | 3/182 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 10/180 | 6/182 |
Full analysis set: All participants who were randomized and received at least one dose of the study drug. 3 participants discontinued the study prior to receiving the study drug and are not included in the full analysis set.
| Age, Categorical(Participants) | Anifrolumab 300 mg | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 175 | 181 | 356 |
| >=65 years | 5 | 1 | 6 |
| Age, Continuous(Years) | Anifrolumab 300 mg | Placebo | Total |
|---|---|---|---|
| Mean | 43.1 ± 11.95 | 41.1 ± 11.47 | 42.1 ± 11.74 |
| Sex: Female, Male(Participants) | Anifrolumab 300 mg | Placebo | Total |
|---|---|---|---|
| Female | 168 | 170 | 338 |
| Male | 12 | 12 | 24 |
| Ethnicity (NIH/OMB)(Participants) | Anifrolumab 300 mg | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 54 | 54 | 108 |
| Not Hispanic or Latino | 118 | 120 | 238 |
| Unknown or Not Reported | 8 | 8 | 16 |
| Race/Ethnicity, Customized(Participants) | Anifrolumab 300 mg | Placebo | Total |
|---|---|---|---|
| White | 110 | 107 | 217 |
| Black or African American | 17 | 25 | 42 |
| Asian | 30 | 30 | 60 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| American Indian or Alaska Native | 4 | 1 | 5 |
| Other | 11 | 11 | 22 |
| Missing | 8 | 8 | 16 |
| Geographic region(Participants) | Anifrolumab 300 mg | Placebo | Total |
|---|---|---|---|
| Asia Pacific | 27 | 26 | 53 |
| Europe | 51 | 46 | 97 |
| Latin America | 35 | 32 | 67 |
| United States/Canada | 64 | 68 | 132 |
| Rest of World (South Africa) | 3 | 10 | 13 |
Showing the first 100 of 113 sites across 15 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2015 to primary completion in Sep 2018, 38 months.
Results were first posted in Mar 2020, 1 year 5 months after primary completion. A results delay was requested in Aug 2019.
Of 53 phase 3 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 84. This study's 38 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Anifrolumab
Lupus Erythematosus, Systemic →